Crispr delivery and manufacturing innovation for minimal-COG cancer and HIV therapies via in vivo immune engineering
Active Other Transaction Agreement Awarded Last action
- Contract number
- 140D042590005
- Awardee
-
Global Life Sciences Solutions USA LLC UEI FG41DG32EGC3
- Awarding agency
-
Interior Business Center
Office of Policy Management and Budget, Department of the Interior
- Obligated
- $15,910,690
Award facts
- Contract value 40% obligated
-
- $15,910,690.00 Current, with exercised options
- $40,130,860.00 Potential, with all options
- Completion date 18% complete
-
- Current, with exercised options
- Potential, with all options
- Funding agency
- National Institutes of Health Department of Health and Human Services
- NAICS code
- Not on record
- Competition
- Competed Program Solicitation
- Pricing
- Other
- Place of performance
- Marlborough, MA 01752, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Other Administrative Action | $0 | |
| Original award | $15,910,690 |
About this award
The National Institutes of Health awarded an Other Transaction Agreement to Global Life Sciences Solutions USA LLC for $40,130,860 to develop CRISPR delivery and manufacturing innovation for minimal-cost cancer and HIV therapies via in vivo immune engineering, with an award date of September 25, 2025.
The agreement runs through September 24, 2031 and is performed in Marlborough, Massachusetts. As an OTA, this agreement operates outside the Federal Acquisition Regulation and represents a mechanism for advanced research and development collaboration with industry. Global Life Sciences Solutions, a wholly owned subsidiary of Danaher Corporation, specializes in advanced scientific equipment, chromatography systems, cell processing devices, and biological materials for federal research institutions. The company's core capability portfolio includes protein purification and chromatography systems, surface plasmon resonance instruments, controlled-rate freezers, cell processing equipment, and fluorescence imaging systems—technologies foundational to bioprocess innovation in cell and gene therapy manufacturing. This OTA reflects NIH's strategic focus on reducing manufacturing costs and improving delivery mechanisms for emerging immunotherapies targeting high-burden diseases.
Quick answers
Who was awarded contract 140D042590005?
140D042590005 was awarded to Global Life Sciences Solutions USA LLC by Interior Business Center (Office of Policy Management and Budget) on September 25, 2025.
How much is contract 140D042590005 worth?
The government has obligated $15,910,690 on 140D042590005. Its potential value, with all options, is $40,130,860.
Which agency awarded contract 140D042590005?
Interior Business Center (Office of Policy Management and Budget) awarded 140D042590005, with funding from National Institutes of Health (Department of Health and Human Services).
Was contract 140D042590005 competed?
The extent of competition for 140D042590005 was competed.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award